A Study Evaluating Gene Therapy With BB305 Lentiviral Vector in Sickle Cell Disease
Clinical trial NCT04293185 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04293185
- Sponsor
- Genetix Biotherapeutics Inc.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-02-14
- Primary completion
- 2027-05-01
- Enrollment
- 35
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.